Brokerages Set argenx SE (NASDAQ:ARGX) PT at $530.74

argenx SE (NASDAQ:ARGX) has received an average recommendation of “Moderate Buy” from the twenty-one analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, fourteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $528.16.

ARGX has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $451.00 price target on shares of argenx in a research report on Thursday. Wells Fargo & Company raised their price target on shares of argenx from $472.00 to $478.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 20th. Robert W. Baird reduced their price target on shares of argenx from $505.00 to $490.00 and set an “outperform” rating on the stock in a research report on Friday, March 1st. Wolfe Research initiated coverage on shares of argenx in a research report on Thursday, February 15th. They issued a “peer perform” rating on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $521.00 price objective on shares of argenx in a research report on Thursday.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Nkcfo LLC increased its position in shares of argenx by 22.1% in the third quarter. Nkcfo LLC now owns 116 shares of the company’s stock worth $57,000 after acquiring an additional 21 shares in the last quarter. Genus Capital Management Inc. grew its position in argenx by 1.6% during the third quarter. Genus Capital Management Inc. now owns 1,605 shares of the company’s stock valued at $789,000 after purchasing an additional 25 shares in the last quarter. Creative Planning grew its position in argenx by 3.0% during the fourth quarter. Creative Planning now owns 1,006 shares of the company’s stock valued at $381,000 after purchasing an additional 29 shares in the last quarter. Snowden Capital Advisors LLC grew its position in argenx by 1.9% during the first quarter. Snowden Capital Advisors LLC now owns 1,920 shares of the company’s stock valued at $715,000 after purchasing an additional 35 shares in the last quarter. Finally, Wahed Invest LLC grew its position in argenx by 9.6% during the fourth quarter. Wahed Invest LLC now owns 457 shares of the company’s stock valued at $174,000 after purchasing an additional 40 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Price Performance

Shares of ARGX stock opened at $360.23 on Wednesday. The firm has a market cap of $21.36 billion, a P/E ratio of -70.08 and a beta of 0.65. argenx has a 1-year low of $327.73 and a 1-year high of $550.76. The firm has a fifty day moving average of $387.43 and a two-hundred day moving average of $420.93.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.45). argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. The company had revenue of $417.84 million for the quarter, compared to analyst estimates of $378.60 million. During the same period in the prior year, the business earned ($0.70) earnings per share. On average, sell-side analysts expect that argenx will post -2.11 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.